Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Celecoxib long-acting injectable - Arthritis Innovation Corporation/MedinCell

Next Previous
Drug Profile

Celecoxib long-acting injectable - Arthritis Innovation Corporation/MedinCell

Alternative Names: F-14; mdc CWM

Latest Information Update: 13 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedinCell S.A.
  • Developer Arthritis Innovation Corporation
  • Class Antimigraines; Antineoplastics; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Postoperative pain
  • Phase II Inflammation

Most Recent Events

  • 09 Dec 2024 Efficacy data from phase III trial in Postoperative pain released by MedinCell
  • 09 Dec 2024 Medincell plans subgroup analysis clinical trial in 2025
  • 03 Sep 2024 MedinCell completes a phase III trial in Postoperative pain (Combination therapy) in USA (Intra-articular) before September 2024 (NCT05603832)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top